SYRS (Syros Pharmaceuticals) LT-Debt-to-Total-Asset: 0.68 (As of Sep. 2024)


SYRS Syros Pharmaceuticals Inc SYRS
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals LT-Debt-to-Total-Asset?

Syros Pharmaceuticals SYRS 12 LT-Debt-to-Total-Asset is 0.68 as of Sep. 2024. GuruFocus rates SYRS with a GF Score™ of 12/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Syros Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.68.

Syros Pharmaceuticals's long-term debt to total assets ratio increased from Sep. 2023 (0.40) to Sep. 2024 (0.68). It may suggest that Syros Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Syros Pharmaceuticals  (OTCPK:SYRS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Syros Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Syros Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals LT-Debt-to-Total-Asset Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.30 0.35 0.25 0.32

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.32 0.35 0.55 0.68
SYRS
12GF Score
Syros Pharmaceuticals Inc SYRS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Syros Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=53.084/168.174
=0.32

Syros Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=57.642/84.995
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.68 mean?
Syros Pharmaceuticals (SYRS) has a LT-Debt-to-Total-Asset of 0.68 as of Sep. 2024. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Syros Pharmaceuticals and its competitors.
Is Syros Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Syros Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.68. Overall, Syros Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Syros Pharmaceuticals' LT-Debt-to-Total-Asset compare to AFMDQ and BTAX?
Syros Pharmaceuticals' LT-Debt-to-Total-Asset of 0.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Syros Pharmaceuticals and its competitors. Syros Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syros Pharmaceuticals stock overvalued right now?
Syros Pharmaceuticals (SYRS) has a current LT-Debt-to-Total-Asset of 0.68. The current LT-Debt-to-Total-Asset is 0.68. Syros Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Syros Pharmaceuticals (SYRS), the current LT-Debt-to-Total-Asset is 0.68 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for SYRS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price